# EDGAR Filing Document

**Accession Number:** 0001322505
**File Stem:** 0001193125-23-058267
**Filing Date:** 2023-3
**Character Count:** 12152
**Document Hash:** 4ee7694ef3bdbc16d1df7136c48a3284
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-058267.hdr.sgml**: 20230302

**ACCESSION NUMBER**: 0001193125-23-058267

**CONFORMED SUBMISSION TYPE**: S-8 POS

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230302

**DATE AS OF CHANGE**: 20230302

**EFFECTIVENESS DATE**: 20230302

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALBIREO PHARMA, INC.
- **CENTRAL INDEX KEY:** 0001322505
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8 POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-263147
- **FILM NUMBER:** 23699799

**BUSINESS ADDRESS:**
- **STREET 1:** 10 POST OFFICE SQUARE
- **STREET 2:** SUITE 502 SOUTH
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109
- **BUSINESS PHONE:** 857-415-4774

**MAIL ADDRESS:**
- **STREET 1:** 10 POST OFFICE SQUARE
- **STREET 2:** SUITE 502 SOUTH
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biodel Inc
- **DATE OF NAME CHANGE:** 20050331

**As filed with the Securities and Exchange Commission on March 2, 2023** 

**Registration Nos. 333- 263147** 

**333- 253500** 

**333- 233111** 

**333- 228280** 

**333- 226718** 

**333- 222131** 

**333- 215264** 

**333- 180409** 

**333- 168903** 

**333-144407** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

------

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333- 263147** 

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333- 253500** 

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333- 233111** 

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333- 228280** 

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333- 226718** 

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333- 222131** 

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333- 215264** 

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-180409** 

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-168903** 

**Post-Effective Amendment No. 1 to Form S-8, Registration Statement No. 333-144407** 

------

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

------

## Albireo Pharma, Inc.
**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware** | **90-0136863** |
| **(State or other jurisdiction of<br>incorporation)** | **(IRS Employer<br>Identification No.)** |

---

**53 State Street, 19<sup>th</sup> Floor** 

**Boston, Massachusetts 02109** 

**(Address, including zip code, of principal executive offices)** 

**Registrant's telephone number, including area code: (857) 254-5555** 

**2020 Inducement Equity Incentive Plan** 

**Non-Qualified Stock Option Agreement dated October 10, 2018** 

**Restricted Stock Unit Agreement dated October 10, 2018** 

**2018 Equity Incentive Plan, as amended** 

**2018 Equity Incentive Plan** 

**2018 Employee Stock Purchase Plan** 

**2017 Inducement Equity Incentive Plan** 

**2016 Equity Incentive Plan** 

**Amended and Restated 2010 Stock Incentive Plan** 

**2010 Stock Incentive Plan** 

**2005 Employee Stock Purchase Plan** 

**2005 Non-Employee Directors' Stock Option Plan** 

**2004 Stock Incentive Plan** 

**(Full titles of plans)** 

**Ronald H.W. Cooper** 

**Albireo Pharma, Inc.** 

**53 State Street, 19<sup>th</sup> Floor** 

**Boston, Massachusetts 02109** 

**(857) 254-5555** 

**(Name and address, including zip code, and telephone number, including area code, of agent for service)** 

***With copies to:***

---

| | |
|:---|:---|
| **Tony Chan, Esq.**<br> **Orrick, Herrington & Sutcliffe LLP**<br> **Columbia Center**<br> **1152 15th Street, N.W.**<br> **Washington, DC 20005-1706** | **Niki Fang, Esq.**<br> **Lynne T. Hirata, Esq.**<br> **Orrick, Herrington & Sutcliffe LLP**<br> **405 Howard Street**<br> **San Francisco, CA 94105-2669** |

---

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**DEREGISTRATION OF SECURITIES** 

These post-effective amendments (the "**Post-Effective Amendments**") are being filed by Albireo Pharma, Inc., a Delaware corporation (the "**Registrant**"), to remove from registration all shares of the Registrant's common stock, $0.01 par value per share (the "**Shares**"), remaining unissued and unsold under the following Registration Statements on Form S-8 (the "**Registration Statements**") filed by the Registrant with the Securities and Exchange Commission (the "**SEC**"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. [333-263147](http://www.sec.gov/Archives/edgar/data/1322505/000110465922028667/tm227642d1_s8.htm) , filed on March 1, 2022, registering 3,000,000 Shares, issuable pursuant to the 2018 Equity
Incentive Plan, as amended;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. [333-253500](http://www.sec.gov/Archives/edgar/data/1322505/000110465921028228/tm217904d3_s8.htm) , filed on February 25, 2021, registering 300,000 Shares, consisting of: (i) 97,000 Shares
underlying options granted under the 2020 Inducement Equity Incentive Plan and (ii) 203,000 Shares underlying options to be granted under the 2020 Inducement Equity Incentive Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. [333-233111](http://www.sec.gov/Archives/edgar/data/1322505/000110465919044748/a19-16558_1s8.htm) , filed on August 8, 2019, registering 2,100,000 Shares, issuable pursuant to the 2018
Equity Incentive Plan, as amended;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. [333-228280](http://www.sec.gov/Archives/edgar/data/1322505/000110465918067016/a18-39564_1s8.htm) , filed on November 8, 2018, registering 42,500 Shares, consisting of: (i) 37,500
Shares underlying options granted under the Non-Qualified Stock Option Agreement dated as of October 10, 2018, by and between Registrant and the recipient identified therein and
(ii) 5,000 Shares issuable upon the vesting of restricted stock units granted under the Restricted Stock Unit Agreement dated October 10, 2018, by and between the Registrant and recipient identified therein;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. [333-226718](http://www.sec.gov/Archives/edgar/data/1322505/000119312518244302/d592872ds8.htm) , filed on August 9, 2018, registering 2,506,088 Shares, consisting of: (i) 443,550 Shares
underlying options granted under the 2018 Equity Incentive Plan, (ii) 1,762,538 Shares underlying options to be granted under the 2018 Equity Incentive Plan and (iii) 300,000 Shares issuable pursuant to the 2018 Employee Stock Purchase Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. [333-222131](http://www.sec.gov/Archives/edgar/data/1322505/000119312517372043/d512251ds8.htm) , filed on December 18, 2017, registering 150,000 Shares, underlying options or stock-based
awards to be granted under the 2017 Inducement Equity Incentive Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. [333-215264](http://www.sec.gov/Archives/edgar/data/1322505/000156459016030443/albo-s8.htm) , filed on December 22, 2016, registering 1,366,738 Shares, , consisting of: (i) 207,725 Shares
underlying options granted under the 2016 Equity Incentive Plan, (ii) 676,334 Shares underlying options to be granted under the 2016 Equity Incentive Plan and (iii) 482,679 Shares underlying options granted under the Amended and Restated 2010 Stock
Incentive Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. [333-180409](http://www.sec.gov/Archives/edgar/data/1322505/000114544312000272/d29314.htm) , filed on March 28, 2012, registering 1,096,756 Shares, issuable pursuant to the 2010 Stock
Incentive Plan;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. [333-168903](http://www.sec.gov/Archives/edgar/data/1322505/000095012310078549/y86175sv8.htm) , filed on August 17, 2010, registering 5,400,00 Shares, issuable pursuant to the 2010 Stock
Incentive Plan; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration Statement No. [333-144407](http://www.sec.gov/Archives/edgar/data/1322505/000095012307009661/y36878sv8.htm) , filed on July 6, 2007, registering 6,500,000 Shares, consisting of: (i) 1,300,000 Shares
issuable pursuant to the 2005 Employee Stock Purchase Plan, (ii) 1,410,973 Shares underlying options granted under the 2004 Stock Incentive Plan, (iii) 3,289,027 Shares underlying options to be granted under the 2004 Stock Incentive Plan, (iv)
200,000 Shares underlying options granted under the 2005 Non-Employee Directors' Stock Option Plan and (v) 300,000 Shares underlying options to be granted under the 2005 Non-Employee Directors' Stock Option Plan.

------

On March 2, 2023, pursuant to the terms of the Agreement and Plan of Merger, dated as of January 8, 2023, by and among the Registrant, Ipsen Biopharmaceuticals, Inc., a Delaware corporation ("**Ipsen**") and wholly-owned subsidiary of Ipsen Pharma SAS, a French *société par actions simplifiée* ("**Guarantor**"), Anemone Acquisition Corp., a Delaware corporation and a wholly-owned subsidiary of Ipsen ("**Purchaser**") and for certain purposes thereunder, Guarantor, Purchaser merged with and into the Registrant (the "**Merger**"), with the Registrant continuing as the surviving corporation and a wholly-owned subsidiary of Ipsen. As a result of the Merger, the offerings pursuant to the Registration Statements have been terminated. In accordance with an undertaking made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the Shares registered under the Registration Statements that remain unsold at the termination of the offerings, the Registrant hereby removes from registration the Shares registered but unsold under the Registration Statements as of the date hereof, if any. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.

In addition, on March 2, 2023 the Nasdaq Stock Market filed a Form 25 to delist the Registrant's Shares.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on March 2, 2023.

---

| | |
|:---|:---|
| ALBIREO PHARMA, INC. | ALBIREO PHARMA, INC. |
| By: | /s/ Christelle Huguet |
|  | Name: Christelle Huguet |
|  | Title: President |

---

No other person is required to sign these Post-Effective Amendments in reliance upon Rule 478 under the Securities Act of 1933, as amended.